Recent studies have linked a rare, but serious group of kidney diseases to a specific dye used during MRI procedures in certain patients. Patients who are dependent on dialysis or who have severe renal failure may be at risk for a group of kidney diseases called Nephrogenic Systemic Fibrosis/Nephrogenic Fibrosing Dermopathy (NSF/NFD) if a gadolinium-based dye is used during an MRI.
Also, the FDA recently cautioned against the use of this gadolinium-based dye in patients with moderately reduced renal function. Therefore all Lifespan partner hospitals have instituted a policy to only use this gadolinium-based dye if necessary for diagnosis, and will limit the dose to the minimum required to properly complete the procedure.
In patients with severe renal failure, exposure to this specific dye slightly increases the risk for NSF. Significant risk is also present for patients with acute renal insufficiency or renal insufficiency due to hepato-renal syndrome. Extreme caution will be used at all times at all Lifespan partner hospitals for patients with acute renal insufficiency related to recent major surgery, vascular procedures, sepsis or in the peri-transplantation period.
Lifespan partner hospitals are committed to high-quality patient care. If you have any questions about gadolinium prior to undergoing an MRI, please contact your physician.